# Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

> **NCT00521274** · PHASE2 · TERMINATED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 11 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **BIOLOGICAL:** MVA 5T4
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00521274
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2008-07
- **Final completion:** 2008-08
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Oxford BioMedica halted TroVax injections
- **Last updated:** 2016-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521274, "Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00521274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*